Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, United States.
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, United States.
Oral Oncol. 2020 Mar;102:104584. doi: 10.1016/j.oraloncology.2020.104584. Epub 2020 Feb 4.
The treatment of locally advanced oral cavity cancer is often multimodal, involving surgical resection, radiotherapy (RT), and chemotherapy. Systemic therapy is the mainstay of treatment for recurrent/metastatic disease. While the concurrent use of cisplatin with post-operative RT is well established in patients with high risk features of extranodal extension and/or positive surgical margins following resection, the role of chemotherapy in other curative settings is not clear. Studies reporting success of induction chemotherapy or definitive chemoradiotherapy in absence of primary resection include all anatomic sites of head and neck cancer, and oral cavity cancer subset is rarely reported as a separate analysis, thus limiting the interpretation of results. This article will focus on the use of systemic therapy for locoregionally advanced oral cavity cancer.
局部晚期口腔癌的治疗通常采用多模态方法，包括手术切除、放疗（RT）和化疗。系统治疗是复发性/转移性疾病的主要治疗方法。虽然在具有淋巴结外扩展和/或切除后手术切缘阳性的高危特征的患者中，顺铂联合术后 RT 的联合应用已得到充分确立，但在其他治愈性环境中化疗的作用尚不清楚。报告在没有原发性切除的情况下诱导化疗或确定性放化疗成功的研究包括头颈部癌症的所有解剖部位，口腔癌亚组很少作为单独分析进行报告，因此限制了对结果的解释。本文将重点介绍系统治疗在局部晚期口腔癌中的应用。
